Search Login Register

rimonabant Summary

Description: a potent & selective antagonist of the brain cannabinoid receptor; structure given in first source

Also Known As: Acomplia; N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride; SR 141716; SR 141716A; SR-141716A; SR141716; SR141716A; Sanofi-Synthelabo brand of rimonabant; Zimulti

Networked: 673 relevant articles (91 outcomes, 152 trials/studies) for this Bio-Agent

Key Diseases for which rimonabant is Relevant

  1. Obesity : 24 outcomes 52 studies in 199 results
  2. Weight Loss (Weight Reduction) : 22 outcomes 47 studies in 137 results
  3. Body Weight (Weight, Body) : 12 outcomes 24 studies in 118 results
  4. Insulin Resistance : 11 outcomes 8 studies in 37 results
  5. Overweight : 5 outcomes 20 studies in 53 results
Show All >>

Drugs Related to rimonabant

  1. CB1 Cannabinoid Receptor (CB1 Receptor)
  2. Glucose (Dextrose)
  3. Triglycerides (Triacylglycerol)
  4. HDL Cholesterol
  5. rimonabant
  6. Endocannabinoids (Endocannabinoid)
  7. Insulin (Novolin)
  8. Cholesterol
  9. Cannabinoid Receptors (Cannabinoid Receptor)
  10. Lipids
Show All >>

Therapies Related to rimonabant

  1. Drug Therapy (Chemotherapy)
  2. Caloric Restriction
  3. Self Administration (Administration, Self)
  4. Ganglionectomy
  5. Vagotomy
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.